Understanding Gadolinium-Based Contrast Agents: A Primer for Health-System Pharmacists
This activity is supported by an educational grant from Guerbet LLC.
Understanding Gadolinium-Based Contrast Agents: A Primer for Health-System Pharmacists
Emanuel Kanal, MD, FACR, FISMRM, AANG
Director, Magnetic Resonance Services
Professor of Radiology and
Neuroradiology
Department of Radiology
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Educational Objectiaves
At the conclusion of this educational activity, participants should be able to:
- Explain the clinical benefit of neuroradiologic gadolinium-based contrast agents (GBCAs), and the differences among available products
- Recall the relationship between GBCAs and nephrogenic systemic fibrosis (NSF)
- Recognize differences among the FDA-approved neuroradiologic GBCAs and their NSF—related risks
- Recognize late-breaking concerns regarding the safety of GBCAs
Target audience:
Pharmacists
Type of activity:
Knowledge
Release date:
January 6, 2015
Expiration date:
January 6, 2017
Estimated time to complete activity:
2.0 hour
Fee:
This lesson is offered free at www.pharmacytimes.org
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-15-113-H04-P. The activity is available for CE credit through January 6, 2017.
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025